Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of APSV in Vaccinia-Naive Adults
NCT00050518Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Feb 2003
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of wetvax in smallpox (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Cutaneous Lesion Formation ('Take') and Safety and Adverse Events at Day 56. Status: completed.
02
Drugs
wetvax
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00050518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050518.